A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
Mocroft, A;
Reiss, P;
Rakhmanova, A;
Banhegyi, D;
Phillips, AN;
De Wit, S;
Ristola, M;
Lundgren, JD;
Grarup, J;
Kirk, O;
+1 more...EuroSIDA in EuroCOORD;
(2014)
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
Infection, 42 (4).
pp. 757-762.
ISSN 0300-8126
DOI: https://doi.org/10.1007/s15010-014-0630-4
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.
